menu search

Jnk: the fed supports a bullish rating

The article evaluates the SPDR Bloomberg Barclays High Yield Bond ETF as an investment option at its cu...

November 3, 2023, 10:02 am

Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann

Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for t...

November 3, 2023, 10:00 am

Unlocking q3 potential of ebay (ebay): exploring wall street estimates for key metrics

Beyond analysts' top -and-bottom-line estimates for eBay (EBAY), evaluate projections for some of its k...

November 2, 2023, 3:02 pm

Exploring analyst estimates for cargurus (carg) q3 earnings, beyond revenue and eps

Beyond analysts' top -and-bottom-line estimates for CarGurus (CARG), evaluate projections for some of i...

November 2, 2023, 3:02 pm

Axon (axon) q3 earnings preview: what you should know beyond the headline estimates

evaluate the expected performance of Axon (AXON) for the quarter ended September 2023, looking beyond t...

November 2, 2023, 2:17 pm

Akamai technologies (akam) q3 earnings on the horizon: analysts' insights on key performance measures

Beyond analysts' top -and-bottom-line estimates for Akamai Technologies (AKAM), evaluate projections fo...

November 2, 2023, 1:33 pm

Steris (ste) q2 earnings preview: what you should know beyond the headline estimates

Beyond analysts' top -and-bottom-line estimates for Steris (STE), evaluate projections for some of its ...

November 2, 2023, 12:47 pm

Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – SAN DIE...

November 2, 2023, 11:30 am

Cigna (ci) q3 earnings preview: what you should know beyond the headline estimates

evaluate the expected performance of Cigna (CI) for the quarter ended September 2023, looking beyond th...

November 1, 2023, 1:32 pm

Gear up for fortinet (ftnt) q3 earnings: wall street estimates for key metrics

evaluate the expected performance of Fortinet (FTNT) for the quarter ended September 2023, looking beyo...

November 1, 2023, 1:32 pm

Ahead of exelon (exc) q3 earnings: get ready with wall street estimates for key metrics

evaluate the expected performance of Exelon (EXC) for the quarter ended September 2023, looking beyond ...

November 1, 2023, 12:02 pm

Gear up for atlassian (team) q1 earnings: wall street estimates for key metrics

evaluate the expected performance of Atlassian (TEAM) for the quarter ended September 2023, looking bey...

November 1, 2023, 12:02 pm

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Curious about lilly (lly) q3 performance? explore wall street estimates for key metrics

evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond t...

November 1, 2023, 10:34 am

Stay ahead of the game with stryker (syk) q3 earnings: wall street's insights on key metrics

evaluate the expected performance of Stryker (SYK) for the quarter ended September 2023, looking beyond...

November 1, 2023, 9:46 am

Ozempic just shrugged off a challenge from viatris. what does this mean for investors?

Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be ...

October 31, 2023, 5:05 am

Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluate<...

October 30, 2023, 3:11 pm

Vde: after the pullback, energy is a no-brainer (rating upgrade)

The article evaluates the Vanguard Energy ETF as an investment option at its current market price. The ...

October 30, 2023, 10:21 am

Xencor: data in early 2024 could bring shareholder value

Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate sh...

October 27, 2023, 11:56 am

Xrt: retail is still not where i want to be

The article evaluates the SPDR S&P Retail ETF as an investment option at its current market price. The ...

October 27, 2023, 5:09 am


Search within

Pages Search Results: